Subscribe to:
• POZ magazine • E-newsletters
POZ Personals Sign In / Join
Username:
 Password:

Back to home » Archives » POZ Magazine issues



Table of Contents

The Good Doctor

Dying for a Vaccine

Ashok to the System

Banking on Disaster

International Dream Team 1998

Not Your Average Joe

S.O.S.

To the Editor

Conference Call

Poz Picks

AIDS Is Over

Mourning Star

Obits

Penny Wose, Pound Foolish

River Runs Dry

In the Blood

Nine Lives

Off the Shelf

Power Nutrients

Saved by the Cell

Time Warp

Catch Air!

Urine Luck

External Affairs

HIV, Sir!

Phone Sex

Germs in Sperm

Autograph Book

Baby Dolls

No Needles

POZ Partner

Strike a Pose

CPR for HAART Failure

Salvadoran Savior

POZ Index

Indelicate Balance

Mistruths and Consequences

Positive Planet



Most Talked About

Magic Johnson Accused of Faking HIV (42)

World AIDS Day: Your Feedback (22)

Guidelines Prediction: Start Treatment Earlier (blog) (19)

My First Facebook Demo (blog) (18)

Bone Marrow Transplant: Potential AIDS Cure? (9)

Obama Campaign Set to Boost Domestic HIV/AIDS Funding (8)

Most Popular Lessons

The HIV Life Cycle

Herpes Simplex Virus

Human Papilloma Virus (HPV)

Shingles

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)


emailrssprint

July 1998


Baby Dolls

Glaxo Wellcome slashes cost of AZT in Third World

A Thailand study by the CDC and UNAIDS revealed that a shorter-than-usual course of AZT—in the last four weeks of pregnancy and during labor—cut the risk of mom-to-infant HIV transmission by 50 percent. The results, though not as dramatic as the 70 percent reduction with the longer, more costly course reported by a 1994 U.S. study, offer a feasible alternative for developing countries—where 90 percent of HIV infections occur. The shorter version costs about $80 per woman; the prolonged course about $800.

Due to the trial’s success, officials from the CDC, UNAIDS and the National Institutes of Health recommended that placebo use—a controversial practice slammed by many as unethical—be halted in all six mother-to-child transmission studies worldwide. “This confirms what we’ve been saying for a year—that some short regimen would be better than nothing,” said Dr. Peter Lurie, research associate at Public Citizen's Health Research Group. “If the CDC had paid heed, we wouldn’t have dozens of infected infants.”  

After an activist uproar, Glaxo Wellcome slashed the cost of AZT for pregnant women with HIV in developing countries—the first time a large drug company has discounted the price of an AIDS med to get it to hard-hit regions. The company also announced it will consider chopping the price of 3TC if that med proves similarly effective.

emailrssprint

[Go to top]

Get Started
Get Answers
What to do if you've just been diagnosed
How to find a support system
Things you should know before starting treatment
How to handle side effects and other concerns
How to tell someone you have HIV/AIDS

Talk to Us
Weekly Poll
Question: Would legalizing prostitution reduce the spread of HIV?
Yes
No
I don't know.
Monthly Poll
Question: Do you believe that prisoners receive adequate health care?
Yes
No
I don't know.
Surveys
Tell us about your overall health habits.

Tell us when and to whom you disclose your status.

more surveys
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertise/contact us | site map]
© 2008 Smart + Strong. All Rights Reserved. Terms of use and Your privacy